Post Hoc Assessment of Time to Clinical Response Among Adults Hospitalized with Community-Acquired Bacterial Pneumonia Who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials

Efficacy and Safety of IV-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for Treatment of Community-Acquired Bacterial Pneumonia: The Phase 3 LEAP 1 Trial

(2019) Thomas M File et al.   CLINICAL INFECTIOUS DISEASES

Lefamulin: Review of a promising novel pleuromutilin antibiotic

(2018) Michael P. Veve et al.   PHARMACOTHERAPY

The relative burden of community-acquired pneumonia hospitalizations in older adults: a retrospective observational study in the United States

(2018) Joshua D. Brown et al.   BMC Geriatrics

Lefamulin: a promising new pleuromutilin antibiotic in the pipeline

(2018) Caroline Dillon et al.   Expert Review of Anti-Infective Therapy

The Early Clinical Response Endpoint: Great Timing by the Food and Drug Administration?

(2016) George H. Talbot   CLINICAL INFECTIOUS DISEASES

Clinical and economic burden of community-acquired pneumonia in the Veterans Health Administration, 2011: a retrospective cohort study

(2015) John M. McLaughlin et al.   INFECTION

Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis

(2015) Ayelet Raz-Pasteur et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Setting Value-Based Payment Goals — HHS Efforts to Improve U.S. Health Care

(2015) Sylvia M. Burwell   NEW ENGLAND JOURNAL OF MEDICINE

Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults

(2015) Seema Jain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Relationship between Time to Clinical Response and Outcomes among Pneumonia Outcomes Research Team (PORT) Risk Class III and IV Hospitalized Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and Azithromycin

(2014) Evan Zasowski et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Assessment of Time to Clinical Response, a Proxy for Discharge Readiness, among Hospitalized Patients with Community-Acquired Pneumonia Who Received either Ceftaroline Fosamil or Ceftriaxone in Two Phase III FOCUS Trials

(2014) Thomas P. Lodise et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Prevalence of Antimicrobial Use in US Acute Care Hospitals, May-September 2011

(2014) Shelley S. Magill et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Community-Acquired Pneumonia Episode Costs by Age and Risk in Commercially Insured US Adults Aged ≥50 Years

(2013) Reiko Sato et al.   Applied Health Economics and Health Policy

Association Between Time to Clinical Stability and Outcomes After Discharge in Hospitalized Patients With Community-Acquired Pneumonia

(2011) Stefano Aliberti et al.   CHEST

Predictors of Short-term Rehospitalization Following Discharge of Patients Hospitalized With Community-Acquired Pneumonia

(2009) Alberto Capelastegui et al.   CHEST